It should not be construed as financial, legal or other professional advice, nor is it intended to recommend the purchase of any specific product or service
Participants must be adults aged 1875 with moderately to severely active UC confirmed by endoscopy and histology, having at least 15 cm disease extent from anal verge, modified MS of 59 points with MES of at least 2, and inadequate response or intolerance to prior treatments including corticosteroids, immunomodulators, or advanced therapies, while excluding those with CD, toxic megacolon, prior vedolizumab exposure, or contraindicated medications, with the study completing primary outcomes in October 2025 and final completion estimated for February 2027
Recent Updates Eli Lilly's Strategic Expansion: Eli Lilly's $6.5 billion investment in a new manufacturing facility underscores its commitment to scaling production of GLP-1 therapies
Wegovy prescription with one of our board-certified doctors
The best place to buy tirzepatide should ultimately signify cooperating with providers genuinely prioritizing your health and wellbeing